Multiple Myeloma Clinical Trial

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Summary

This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.

View Full Description

Full Description

During the Phase I portion of this clinical trial, the doses of Revlimid® and Doxil® will be increased until the best and safest amount (or dose) is identified in combination with Velcade® and Dexamethasone. "Investigational" means that the drug combination is still being studied and that research doctors are trying to find out more about it such as the safest dose to use, the side effects it may cause and how effective the Velcade®, Doxil®, Dexamethasone and Revlimid® investigational combination is for treating newly diagnosed multiple myeloma. In this clinical trial we are looking for the highest dose of the combination that can be given safely and see how well it works as a combination in newly diagnosed patients.

Each of these drugs, Velcade®, Doxil®, Dexamethasone and Revlimid® are approved by the FDA (U.S. Food and Drug Administration). They have not been approved in this combination for use for your type of cancer or any other type of cancer. Velcade® is currently approved by the United States Food and Drug Administration (US FDA) for the treatment of multiple myeloma patients who have received at least one prior therapy. Doxil® has recently been approved by the US FDA for multiple myeloma in combination with Velcade® in patients who have not previously received Velcade® and have received at least one prior therapy. Dexamethasone is commonly used, either alone, or in combination with other drugs, to treat multiple myeloma. Revlimid® is currently approved by the US FDA in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least 1 prior therapy.

After the Phase I clinical trial defines the safest doses of Velcade®, Doxil®, Dexamethasone and Revlimid® that can be taken together, the research study will move on to its second portion, a Phase II clinical trial. The Phase II portion of the clinical trial will test the clinical effectiveness of the best dose combination of the four drugs.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

At least 18 years of age at the time of consent
Measurable disease
All necessary baseline studies completed
LVEF (left ventricular ejection fraction) greater than or equal to 50 percent by MUGA (multigated acquisition scan) or ECHO (echocardiogram)
Must be able to adhere to study visit schedule

Exclusion

Greater than or equal to grade 2 peripheral neuropathy on clinical examination within 14 days of enrollment
Renal insufficiency
Evidence of mucosal or internal bleeding and/ or platelet refractory.
Absolute neutrophil count less than 1000 cells/mm^2 within 14 days of enrollment.
Acceptable labs
Concomitant medications that include corticosteroids
Myocardial infarction within 6 months prior to enrollment, uncontrolled angina, severe uncontrolled ventricular arrhythmias
Clinically relevant active infection or serious medical condition that places the subject at unacceptable risk
Any condition, including laboratory values that places the subject at an unacceptable risk
Another malignancy within 3 years of enrollment, with the exception of the complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy
Hypersensitivity to bortezomib, boron, or mannitol or any of the components of DOXIL
Female subject that is pregnant or breastfeeding.
Can not have received any other investigational drugs within 14 days of enrollment
Serious medical or psychiatric illness
Uncontrolled diabetes mellitus
Hypersensitivity to acyclovir or similar antiviral drug
POEMS (plasma cell dyscrasia with polyneuropathy)
Known HIV
Known hepatitis B or C
Known intolerance to steroid therapy
Known hypersensitivity to required prophylactic mediations

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

74

Study ID:

NCT00724568

Recruitment Status:

Completed

Sponsor:

University of Michigan Rogel Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Emory University Hospital
Atlanta Georgia, 30322, United States
The University of Chicago Medical Center
Chicago Illinois, 60637, United States
Dana Farber Cancer Institute (and Massachusetts General)
Boston Massachusetts, 02115, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States
The Ohio State University Medical Center
Columbus Ohio, 43210, United States
Princess Margaret Hospital
Toronto Ontario, M5G 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

74

Study ID:

NCT00724568

Recruitment Status:

Completed

Sponsor:


University of Michigan Rogel Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider